LUMIRACOXIB in English translation

• lumiracoxib

Examples of using Lumiracoxib in Danish and their translations into English

In vivo studier antyder, at lumiracoxib har lille potentiale for interaktioner med CYP2C9 substrater.
In vivo studies suggest that lumiracoxib has low potential for interactions with CYP2C9 substrates.

Databaseundersøgelse af anvendelsen af lumiracoxib og andre markedsførte NSAID' s og COX- 2- hæmmere.
To conduct a database study of drug utilisation of lumiracoxib and other marketed NSAIDs and COX-2 inhibitors.

Plasma- proteinbindingen af lumiracoxib hos patienter med terminal nyresygdom svarede til den hos raske frivillige.
Plasma protein binding of lumiracoxib was similar in healthy subjects and in patients with end-stage renal disease.

Uomdannet lumiracoxib er den primære bestanddel af den totale mængde lægemiddelrelaterede materiale i plasma.
Of the total drug related material in plasma, unchanged lumiracoxib is the major component.

Antallet af frafald i TARGET grundet ødem var ikke signifikant forskelligt mellem lumiracoxib(43) og NSAID 55.
The number of discontinuations in TARGET due to oedema was not significantly different between lumiracoxib(43) and NSAIDs 55.

Lumiracoxib 800 mg daglig medførte ingen klinisk betydningsfuld hæmning af den gastriske prostaglandinsyntese og påvirkede ikke trombocytfunktionen.
Lumiracoxib at 800 mg daily did not lead to clinically meaningful inhibition of gastric prostaglandin synthesis and had no effect on platelet function.

Dette indikerer, at lumiracoxib og/ eller dets metabolitter fordeles og forbliver med forskellige
This indicates lumiracoxib and/ or its metabolites are preferentially distributed

Patienter blev behandlet med lumiracoxib i analgetiske kliniske forsøg smerter efter tandoperation, primær dysmenorré
Approximately 1,100 patients were treated with lumiracoxib in analgesia clinical studies post-surgical dental pain,

Antallet af frafald grundet hændelser relateret til hypertension var heller ikke signifikant forskellig mellem lumiracoxib(37) og NSAID 52.
The number of discontinuations due to hypertension-related events was also not significantly different between lumiracoxib(37) and NSAIDs 52.

i disse patienters tilstand, skal der tages relevante forbehold inklusiv seponering af lumiracoxib.
condition of these patients, appropriate measures including discontinuation of lumiracoxib should be taken.

Lumiracoxib påvirker ikke blodtrykskontrollen hos hypertensive patienter og adskilte sig i kliniske forsøg
Lumiracoxib did not affect blood pressure control in hypertensive patients,

Der bør opretholdes medicinsk relevant supervision når lumiracoxib anvendes til ældre og til patienter med mild nyre-, lever- eller hjertedysfunktion.
Medically appropriate supervision should be maintained when using lumiracoxib in the elderly and in patients with mild renal, hepatic, or cardiac dysfunction.

signifikant forskel i incidensen af MI(klinisk MI og ikke symptomgivende MI) mellem lumiracoxib og NSAID.
There was no statistically significant difference between lumiracoxib and NSAIDs for incidence of MI clinical MI and silent MI.

Samtidig administration af lumiracoxib og den potente CYP2C9- hæmmer fluconazol havde ingen klinisk relevant effekt på lumiracoxibs farmakokinetik
Co-administration of lumiracoxib with the potent CYP2C9 inhibitor fluconazole had no clinically relevant effect on the pharmacokinetics

Der er set 33% fald i lumiracoxib Cmax og 27% fald i AUC ved administration af lumiracoxib til patienter med terminal nyresygdom sammenlignet med raske frivillige.
When lumiracoxib was administered to patients with end-stage renal disease, a 33% decrease in lumiracoxib Cmax and a 27% decrease in AUC were observed compared to healthy subjects.

Distribution Lumiracoxib bindes i udstrakt grad til plasmaproteiner(≥98%), og bindingen er koncentrationsuafhængig over spændet 0,
Distribution Lumiracoxib is highly bound to plasma proteins,(≥ 98%),

skal behandling med lumiracoxib seponeres.
persist, lumiracoxib should be discontinued.

På baggrund af in vitro studier, forventes interaktioner med plasma- proteinbinding ikke at have klinisk relevant effekt på lumiracoxib eller samtidigt administrerede lægemidler.
Based on in vitro studies, interactions involving plasma protein binding are not expected to have any clinically relevant effects on lumiracoxib or co-administered drugs.

Lumiracoxib 400 mg har i kliniske forsøg lindret smerte i akutte analgetiske modeller af post- operative tandsmerter,
In clinical studies, lumiracoxib 400 mg relieved pain in acute analgesic models of post-operative dental pain,

Der er administreret gentagne doser af lumiracoxib 1. 200 mg, én gang daglig i 4 uger, til patienter med rheumatoid arthritis uden klinisk signifikante bivirkninger.
Multiple doses of lumiracoxib 1,200 mg once daily have been administered to patients with rheumatoid arthritis for 4 weeks without clinically significant adverse effects.